$PPBT

Return on invested capital % of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0

This page from TradingView displays information related to the Return on Invested Capital (ROIC) percentage for Purple Biotech Ltd. Sponsored ADR, traded on the Munich Stock Exchange under the symbol 1YI0. The content indicates that the market is currently closed and provides navigation to financial data, but the article itself doesn't contain specific ROIC figures or analysis. It largely consists of website navigation and copyright information.

Original reporting
Published Mar 4, 2026, 3:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 4, 2026, 5:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Return on invested capital % of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 — source image
Decision brief

The 30-second read

$PPBTNeutralLow
01

Why it matters

Given the absence of specific data, the impact on trading strategies is minimal.

02

Market read

The news has limited relevance for traders due to its informational nature and lack of actionable data.

03

What to watch

Potential upcoming earnings reports or industry developments could influence the company's stock performance, which are not covered in this news.

Timing: not applicable

Background

The article summarizes the availability of ROIC data for Purple Biotech Ltd. on TradingView, but lacks detailed figures or analysis.

Company-level read

Ticker impact

$PPBTNeutralLow confidence
Context

Limited impact due to low relevance score (0.017984). The news focuses on ROIC data for Purple Biotech Ltd., which does not currently provide actionable insights or significant market movement indications.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

The source offers minimal quantitative data and no technical or fundamental signals to support a trading decision.

$PPBTNeutralLow confidence
Context

Same as above; the news is primarily informational with negligible immediate trading relevance.

Expected impact

No expected impact on stock price.

Evidence & confidence

Insufficient data and lack of analytical content limit the ability to forecast price movements.

Market effects

Minimal, as the news pertains to a specific company's financial metrics without broader sector influence.

None expected; the information is company-specific and does not affect regional markets.

Negligible; limited to company-level data with no global market implications.

Counterpoint

While the current information is limited, some investors might interpret the lack of detailed data as an opportunity to conduct further research before making trading decisions.

Key entities

  • Purple Biotech Ltd.

    A biotechnology company traded on the Munich Stock Exchange under the symbol 1YI0.

Related articles

$PPBTHigh

Why Is Purple Biotech Stock Gaining Wednesday? - Purple Biotech (NASDAQ:PPBT)

Purple Biotech (NASDAQ:PPBT) shares rose 22.89% premarket Wednesday after the U.S. Patent Office granted a Notice of Allowance for its tri-specific antibody constructs. The patent expands the company's IP for its CAPTN-3 platform, which aims to accelerate cancer treatment development. Preclinical data for lead candidate IM1240 showed anti-tumor activity, with human trials planned for 2027.

$PPBTMed

Purple Biotech Ltd.: Purple Biotech Reports Second Quarter 2026 Financial Results

Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2026 results and new preclinical data on its IM1240 tri-specific antibody. The company said IM1240 showed an 8-fold longer half-life and 16-fold higher exposure versus a non-capped variant, with reduced cytokines in toxicology work. Cash was $6.1 million at June 30, 2026, funding a runway to mid-2027. IM1240 is planned for clinical entry in 2027.

$PPBTMed

PURPLE BIOTECH LTD. (PPBT): Financial results for Q2 2026

PURPLE BIOTECH LTD. (PPBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Purple Biotech Reports Second Quarter 2026 Financial Results New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240’s anti-tumor activity, favorable safety a

$PPBTMed

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech presented preclinical EACR 2026 data on its CAPTN-3 program, IM1240. A non-GLP NHP toxicology study validated the CAPTN-3 masking strategy, reporting ~8-fold longer half-life and 16-fold higher exposure versus the non-capped variant IM1222, with markedly lower cytokine release. In patient-derived PD-1/chemo-resistant tumor samples, IM1240 showed anti-tumor activity requiring CD3 and NKG2A, and in NSCLC explants induced mature tertiary lymphoid structures. The company plans first-i

$GMEHighAI 8/10

GameStop CEO Ryan Cohen buys $26.4 million of GME stock

GameStop CEO Ryan Cohen bought 1,150,680 shares, spending $26.4 million, increasing his stake to 40.5 million shares. The stock closed up 0.53% and rose 3% in postmarket trading. Cohen's purchase follows recent insider buying and comes amid GameStop's pursuit of a potential eBay deal. The company's latest quarterly revenue was $790.2 million, down 18.7% year-over-year, but operating income hit a record $160.2 million.